KURA ONCOLOGY, INC.

(KURA)
  Report
Real-time Estimate Cboe BZX  -  02:32 2022-06-27 pm EDT
17.60 USD   -3.14%
06/23KURA ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/26Kura Oncology to Participate in Three Upcoming Investor Conferences
AQ
05/04KURA ONCOLOGY : Q1 Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : Kura Oncology, Inc. Presents at Barclays Global Healthcare Conference 2022, Mar-15-2022 11:15 AM

03/15/2022 | 10:15am EDT
There we go. So I just wanted to thank everybody for attending fireside chat with Kura, attending a conference in Miami. So very grateful everyone came down, and I hope everyone is feeling, feeling...


© S&P Capital IQ 2022
All news about KURA ONCOLOGY, INC.
06/23KURA ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/26Kura Oncology to Participate in Three Upcoming Investor Conferences
AQ
05/04KURA ONCOLOGY : Q1 Earnings Snapshot
AQ
05/04KURA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
05/04TRANSCRIPT : Kura Oncology, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04Kura Oncology Reports First Quarter 2022 Financial Results
AQ
05/04Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/27Kura Oncology to Report First Quarter 2022 Financial Results
AQ
04/08Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergenc..
AQ
04/08Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Em..
CI
More news
Analyst Recommendations on KURA ONCOLOGY, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -148 M - -
Net cash 2022 321 M - -
P/E ratio 2022 -8,27x
Yield 2022 -
Capitalization 1 211 M 1 211 M -
EV / Sales 2022 -
EV / Sales 2023 47,9x
Nbr of Employees 117
Free-Float 94,4%
Chart KURA ONCOLOGY, INC.
Duration : Period :
Kura Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KURA ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 18,17 $
Average target price 35,88 $
Spread / Average Target 97,4%
EPS Revisions
Managers and Directors
Troy E. Wilson Chairman, President, CEO & Chief Financial Officer
Mollie Leoni Senior Vice President-Clinical Development
Stephen Dale Chief Medical Officer
Kathleen Ford Chief Operating Officer
Faheem Hasnain Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
KURA ONCOLOGY, INC.29.79%1 211
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.42%44 742
BIONTECH SE-48.01%32 574